FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3088134426> ?p ?o ?g. }

• W3088134426 endingPage "S488" @default.
• W3088134426 startingPage "S488" @default.
• W3088134426 abstract "Up-regulation of AXL tyrosine kinase expression is observed various tumor types including EGFR-mutant (EGFRm) NSCLC with progressive disease on EGFR tyrosine kinase inhibitors (TKIs), especially in a T790M negative population. Xenograft studies have demonstrated that combined inhibition of AXL and EGFR can overcome and delay the onset of resistance. DS-1205c is a novel, orally administered, highly selective small molecule inhibitor of AXL, and it’s first-in-human clinical study is described here. An ongoing first-in-human, multicenter, open-label, dose escalation Phase 1 study of DS-1205c in combination with gefitinib in metastatic or unresectable EGFRm NSCLC is being conducted. Eligible subjects must have evidence of radiological disease progression during treatment with an EGFR TKI without the T790M resistance mutation. Subjects initially receive DS-1205c monotherapy twice daily (BID) during a run-in period of one week, followed by combination treatment with gefitinib 250 mg once daily. Escalation of DS-1205c dosing is guided by the modified Continuous Reassessment Method using a Bayesian logistic regression model following the escalation with overdose control principle. Primary and secondary endpoints include safety, pharmacokinetics, and preliminary efficacy. Exploratory biomarker analyses include assessment of tumor AXL expression through immunohistochemistry and circulating biomarkers. Dose Escalation in Cohort 1 (200 mg BID; n=5), Cohort 2 (400 mg BID; n=4), Cohort 3 (800 mg BID; n=6), Cohort 4 (1,000 mg BID; n=1), and Cohort 5 (1,200 mg BID; n=4) has been completed as of Apr 8, 2020. One subject in Cohort 3 and 1 subjects in Cohort 5 experienced dose limiting toxicity, and recommended dose for expansion (RDE) was determined as 800 mg BID. There have been no serious adverse events directly related to DS-1205c. Preliminary analysis of efficacy data reveals that one patient had prolonged stable disease beyond 100 days (RECIST v.1.1). Dose Escalation has been completed with the result that RDE is 800 mg BID, and updated clinical and biomarker data will be presented." @default.
• W3088134426 created "2020-10-01" @default.
• W3088134426 creator A5001895894 @default.
• W3088134426 creator A5021644231 @default.
• W3088134426 creator A5025707585 @default.
• W3088134426 creator A5037461196 @default.
• W3088134426 creator A5045577515 @default.
• W3088134426 creator A5048050635 @default.
• W3088134426 creator A5049525954 @default.
• W3088134426 creator A5054574919 @default.
• W3088134426 creator A5058587016 @default.
• W3088134426 creator A5067820808 @default.
• W3088134426 creator A5069589468 @default.
• W3088134426 creator A5072724155 @default.
• W3088134426 creator A5078287634 @default.
• W3088134426 creator A5084498556 @default.
• W3088134426 creator A5071868086 @default.
• W3088134426 date "2020-09-01" @default.
• W3088134426 modified "2023-10-01" @default.
• W3088134426 title "570P A first-in-human phase I study of the AXL inhibitor DS-1205c in combination with gefitinib in subjects with EGFR-mutant NSCLC" @default.
• W3088134426 doi "https://doi.org/10.1016/j.annonc.2020.08.684" @default.
• W3088134426 hasPublicationYear "2020" @default.
• W3088134426 type Work @default.
• W3088134426 sameAs 3088134426 @default.
• W3088134426 citedByCount "5" @default.
• W3088134426 countsByYear W30881344262022 @default.
• W3088134426 countsByYear W30881344262023 @default.
• W3088134426 crossrefType "journal-article" @default.
• W3088134426 hasAuthorship W3088134426A5001895894 @default.
• W3088134426 hasAuthorship W3088134426A5021644231 @default.
• W3088134426 hasAuthorship W3088134426A5025707585 @default.
• W3088134426 hasAuthorship W3088134426A5037461196 @default.
• W3088134426 hasAuthorship W3088134426A5045577515 @default.
• W3088134426 hasAuthorship W3088134426A5048050635 @default.
• W3088134426 hasAuthorship W3088134426A5049525954 @default.
• W3088134426 hasAuthorship W3088134426A5054574919 @default.
• W3088134426 hasAuthorship W3088134426A5058587016 @default.
• W3088134426 hasAuthorship W3088134426A5067820808 @default.
• W3088134426 hasAuthorship W3088134426A5069589468 @default.
• W3088134426 hasAuthorship W3088134426A5071868086 @default.
• W3088134426 hasAuthorship W3088134426A5072724155 @default.
• W3088134426 hasAuthorship W3088134426A5078287634 @default.
• W3088134426 hasAuthorship W3088134426A5084498556 @default.
• W3088134426 hasBestOaLocation W30881344261 @default.
• W3088134426 hasConcept C121608353 @default.
• W3088134426 hasConcept C126322002 @default.
• W3088134426 hasConcept C143998085 @default.
• W3088134426 hasConcept C203092338 @default.
• W3088134426 hasConcept C2776694085 @default.
• W3088134426 hasConcept C2777930144 @default.
• W3088134426 hasConcept C2778820342 @default.
• W3088134426 hasConcept C2779438470 @default.
• W3088134426 hasConcept C2779984678 @default.
• W3088134426 hasConcept C2780580887 @default.
• W3088134426 hasConcept C2908647359 @default.
• W3088134426 hasConcept C31760486 @default.
• W3088134426 hasConcept C535046627 @default.
• W3088134426 hasConcept C71924100 @default.
• W3088134426 hasConcept C72563966 @default.
• W3088134426 hasConcept C99454951 @default.
• W3088134426 hasConceptScore W3088134426C121608353 @default.
• W3088134426 hasConceptScore W3088134426C126322002 @default.
• W3088134426 hasConceptScore W3088134426C143998085 @default.
• W3088134426 hasConceptScore W3088134426C203092338 @default.
• W3088134426 hasConceptScore W3088134426C2776694085 @default.
• W3088134426 hasConceptScore W3088134426C2777930144 @default.
• W3088134426 hasConceptScore W3088134426C2778820342 @default.
• W3088134426 hasConceptScore W3088134426C2779438470 @default.
• W3088134426 hasConceptScore W3088134426C2779984678 @default.
• W3088134426 hasConceptScore W3088134426C2780580887 @default.
• W3088134426 hasConceptScore W3088134426C2908647359 @default.
• W3088134426 hasConceptScore W3088134426C31760486 @default.
• W3088134426 hasConceptScore W3088134426C535046627 @default.
• W3088134426 hasConceptScore W3088134426C71924100 @default.
• W3088134426 hasConceptScore W3088134426C72563966 @default.
• W3088134426 hasConceptScore W3088134426C99454951 @default.
• W3088134426 hasLocation W30881344261 @default.
• W3088134426 hasOpenAccess W3088134426 @default.
• W3088134426 hasPrimaryLocation W30881344261 @default.
• W3088134426 hasRelatedWork W1449776410 @default.
• W3088134426 hasRelatedWork W1815924535 @default.
• W3088134426 hasRelatedWork W1957104301 @default.
• W3088134426 hasRelatedWork W2037355330 @default.
• W3088134426 hasRelatedWork W2058960695 @default.
• W3088134426 hasRelatedWork W2156647409 @default.
• W3088134426 hasRelatedWork W2767731177 @default.
• W3088134426 hasRelatedWork W3137186196 @default.
• W3088134426 hasRelatedWork W3137494729 @default.
• W3088134426 hasRelatedWork W3170053981 @default.
• W3088134426 hasVolume "31" @default.
• W3088134426 isParatext "false" @default.
• W3088134426 isRetracted "false" @default.
• W3088134426 magId "3088134426" @default.
• W3088134426 workType "article" @default.